<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301430</url>
  </required_header>
  <id_info>
    <org_study_id>ParvOryx01</org_study_id>
    <nct_id>NCT01301430</nct_id>
  </id_info>
  <brief_title>Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.</brief_title>
  <acronym>ParvOryx01</acronym>
  <official_title>Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oryx GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oryx GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects
      suffering from glioblastoma multiforme.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects
      suffering from glioblastoma multiforme.

      H-1PV will primarily be administered either intratumoral or intravenously. Ten days
      thereafter a complete or a subtotal tumor resection with a subsequent administration of H-1PV
      into the walls of the resection cavity will be carried out.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 28 days after the first administration of the IMP</time_frame>
    <description>Parameters for assessment of safety and tolerability:
physical/neurological examinations (pathological findings as quality and quantity)
adverse events (quality and quantity per dose level)
vital signs, ECG, laboratory parameters (pathological findings as quality and quantity, for laboratory parameters: descriptive statistics)
viral shedding and viral specific antibodies (quantity depicted over time)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (treatment response)</measure>
    <time_frame>Up to 6 months after the first administration of the IMP</time_frame>
    <description>Parameters for evaluation of efficacy:
Progression free survival (PFS) based on modified RECIST-criteria depicted as Kaplan-Meier curve
Overall survival (OS) depicted as Kaplan-Meier curve</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>H-1 parvovirus (H-1PV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H-1PV</intervention_name>
    <description>H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).</description>
    <arm_group_label>H-1 parvovirus (H-1PV)</arm_group_label>
    <other_name>ParvOryx (brand name of H-1PV)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over or equal to 18 years old,

          -  Diagnosis of glioblastoma multiforme,

          -  Written informed consent,

          -  Recurrent or progressive disease despite previous radio- and/or chemotherapy,

          -  Indication for complete or subtotal tumor resection,

          -  Life expectancy of at least 3 months,

          -  Consent for sampling and investigation of biological specimens,

          -  Karnofsky Performance Score over or equal to 60,

          -  Adequate seizure control,

          -  Adequate bone marrow function: neutrophils &gt; 1.5 x 10exp9/L, platelets &gt; 100 x
             10exp9/L, hemoglobin &gt; 9.0 g/dL,

          -  Adequate liver function: Bilirubin &lt; 2.0 g/dL, ASAT, ALAT, AP, GGT &lt; 3 x ULN,

          -  Adequate renal function: Creatinine &lt; 1.8 g/dL,

          -  Adequate blood clotting: aPTT &lt; 35 sec, INR &lt; 1.2,

          -  Negative serology for HIV, HBV and HCV,

          -  Negative Beta-HCG test in women of childbearing potential,

          -  Commitment to use adequate contraception (in both genders) for up to six months after
             study entry,

          -  Commitment to omit exposure to infants &lt; 18 months of age or immunocompromised
             individuals for up to 28 day after first administration of IMP.

        Exclusion Criteria:

          -  Multifocal disease,

          -  Evidence of distant tumor metastases,

          -  Contraindications for MRI,

          -  Active infection within 5 days prior to the study inclusion,

          -  Chemotherapy within 4 weeks prior to the study inclusion,

          -  Radiotherapy within 6 weeks prior to the study inclusion,

          -  Participation in another interventional trial within the last 30 days,

          -  Treatment with antiangiogenic substances within 21 days prior to therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Unterberg, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurosurgery, University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Huber, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Oryx GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurosurgery, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, Krebs O, von Knebel Doeberitz M, Huber B, Hajda J. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer. 2012 Mar 21;12:99. doi: 10.1186/1471-2407-12-99.</citation>
    <PMID>22436661</PMID>
  </reference>
  <reference>
    <citation>Geletneky K, Leoni AL, Pohlmeyer-Esch G, Loebhard S, Baetz A, Leuchs B, Roscher M, Hoefer C, Jochims K, Dahm M, Huber B, Rommelaere J, Krebs O, Hajda J. Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1. Comp Med. 2015 Feb;65(1):23-35.</citation>
    <PMID>25730754</PMID>
  </reference>
  <reference>
    <citation>Geletneky K, Leoni AL, Pohlmeyer-Esch G, Loebhard S, Leuchs B, Hoefer C, Jochims K, Dahm M, Huber B, Rommelaere J, Krebs O, Hajda J. Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats. Comp Med. 2015 Feb;65(1):36-45.</citation>
    <PMID>25730755</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressive glioblastoma multiforme</keyword>
  <keyword>Recurrent glioblastoma multiforme</keyword>
  <keyword>Oncolytic virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

